Cingulate Inc., a biopharmaceutical company, has filed a prospectus related to the offer and resale of up to 1,000,000 shares of common stock by Lincoln Park Capital Fund, LLC. The shares are par value $0.0001 per share and may be sold at Lincoln Park's discretion. Cingulate Inc. may issue and sell these shares to Lincoln Park based on a purchase agreement dated April 24, 2023. The company will not sell any securities under this prospectus and will not receive proceeds from Lincoln Park's resale of common stock. However, Cingulate may receive up to $10,539,047.82 from the sale of Purchase Shares to Lincoln Park, subject to conditions. The selling price of the shares will fluctuate based on the market price of Cingulate's common...Show More

Cingulate Inc., a biopharmaceutical company, has filed a prospectus related to the offer and resale of up to 1,000,000 shares of common stock by Lincoln Park Capital Fund, LLC. The shares are par value $0.0001 per share and may be sold at Lincoln Park's discretion. Cingulate Inc. may issue and sell these shares to Lincoln Park based on a purchase agreement dated April 24, 2023. The company will not sell any securities under this prospectus and will not receive proceeds from Lincoln Park's resale of common stock. However, Cingulate may receive up to $10,539,047.82 from the sale of Purchase Shares to Lincoln Park, subject to conditions. The selling price of the shares will fluctuate based on the market price of Cingulate's common stock. The prospectus also mentions a 1-for-12 reverse stock split effected on August 9, 2024, and the company's status as an 'emerging growth company' under SEC rules. Investing in the securities involves risks, as detailed in the 'Risk Factors' section starting on page 7 of the prospectus. The date of the prospectus is August 27, 2024.